In this article, we are going to take a look at where N-able, Inc. (NYSE:NABL) stands against the other IT services stocks. According to research firm Statista, the IT Services industry ...
来自MSN7 个月
Clinitech Laboratory Listing: Stock makes decent market debut, lists at 20% premium at ₹115serology, microbiology, and histopathology. The company has been awarded a Certificate of Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) in ...
In a report released yesterday, Matthew Hedberg from RBC Capital maintained a Buy rating on N-able (NABL – Research Report), with a price target of $10.00. The company’s shares closed ...
Scotiabank analyst Joe Vandrick reiterated a Hold rating on N-able (NABL – Research Report) today and set a price target of $8.75. The company’s shares closed yesterday at $7.20. See what ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果